2. World Health Organization. Antibiotic resistance – a threat to global health security. 2013. Accessed Mar 29, 2017. Available from: URL: http://www.who.int/drugresistance/activities/wha66_side_event/en/

3. Bourdin G., Navarro A., Sarker S.A., Pittet A.C., Qadri F., Sultana S., Cravioto A., Talukder K.A., Reuteler G., Brüssow H. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol. 2014;7:165–176. Doi: 10.1111/1751-7915.12113.

4. Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 2009;17:66–72. Doi: 10.1016/j.tim.2008.11.002.

5. Chanishvili N. Phage therapy – history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res. 2012;83:3–40. Doi: 10.1016/B978-0-12-394438-2.0000 1-3.

6. Lin D.M., Koskella B., Lin H.C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–173. Doi: 10.4292/wjgpt.v8.i3.162.

7. Dorothy H. Crawford. Viruses: A Very Short Introduction. Oxford University Press, 2011. 157 s.

8. Delbrück M. The growth of bacteriophage and lysis of the host. J Gen Physiol. 1940;23:643–660.

9. Weinbauer M.G. Ecology of prokaryotic viruses. FEMS Microbiol Rev. 2004;28:127–181. Doi: 10.1016/j.femsre. 2003.08.001.

10. Stejnier R., Jedel'berg Je., Ingrjem D. The world of microbes. 1 tom. M.: Izd-vo «Mir», 1979. 320 s. Russian (Стейниер Р., Эдельберг Э., Ингрэм Д. Мир микробов. T. 1. М.: Изд-во «Мир», 1979. 320 с.).

11. Katter Ye., Sulakvelidze A. Bacteriophages. Biology and practical use. M.: Izd-vo «Nauchnyj mir». 2012. 638 s. Russian (Каттер Э., Сулаквелидзе А. Бактериофаги. Биология и практическое применение. М.: Изд-во «Научный мир». 2012. 638 с.).

12. Penadés J.R., Chen J., Quiles-Puchalt N., Carpena N., Novick R.P. Bacteriophage-mediated spread of bacterial virulence genes. Curr Opin Microbiol 2015;23:171–178. Doi: 10.1016/ j.mib.2014.11.019.

13. Modi S.R., Lee H.H., Spina C.S., Collins J.J. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature 2013;499:219–222. Doi: 10.1038/nature12212.

14. Dorothy H. Crawford. Viruses: A Very Short Introduction. Oxford University Press, 2011. 157 s.

15. Rakhuba D.V., Kolomiets E.I., Dey E.S., Novik G.I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 2010; 59:145–155.

16. Perepanova T.S. Complex treatment and prevention of nosocomial urinary tract infection. Diss. d.m.n. M., 1996. s. 119. Russian (Перепанова Т.С. Комплексное лечение и профилактика госпитальной инфекции мочевых путей. Дисс. д.м.н. М., 1996. с. 119.).

17. Bogovazova G.G. Study of biological properties and therapeutic efficiency of Klebsiella bacteriophages. Diss… kand.med.nauk (v forme nauchnogo doklada). Cheljabinsk, 1993. 27 s. Russian (Боговазова Г.Г. Изучение биологических свойств и терапевтической эффективности препаратов бактериофагов Klebsiella. Дисс. канд. мед.наук (в форме научного доклада). Челябинск, 1993. 27с.).

18. Voroshilova N.N. Bacteriophages and their efficiency for the treatment of intestinal and purulent-septic infectious diseases caused by opportunistic pathogens. Informacionnye materialy. GP «NPO Immunopreparat». Ufa, 1996. 17 s. Russian (Ворошилова Н.Н. Препараты бактериофагов и их эффективность при лечении энтеральных и гнойно-септических инфекционных заболеваний, вызванных условно-патогенными бактериями. Информационные материалы. ГП «НПО Иммунопрепарат». Уфа, 1996. 17 с.).

19. Masoud Sabouri Ghannad, Avid Mohammadi. Bacteriophage: Time to Re-Evaluate the Potential of Phage Therapy as a Promising Agent to Control Multidrug-Resistant Bacteria. Iranian Journal of Basic Medical Sciences www.mums.ac.ir 2012;15(2):693–701.

20. Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8:317–327.

21. Maciejewska B., Olszak T., Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl Microbiol Biotechnol. 2018;102:2563–2581.

22. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2:166–173.

23. Rohde C., Resch G., Pirnay J.P., Blasdel B.G., Debarbieux L., Gelman D.,Gorski A., Hazan R., Huys I., Kakabadze E., Lobocka M., Maestri A., Almeida G.M.F., Makalatia K., Malik D.J., Maslanova I., Merabishvili M.,Pantucek R., Rose T., Stverakova D., Van Raemdonck H., Verbeken G., Chanishvili N. Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses 2018;10 pii: E178. Doi: 10.3390/ v10040178.

24. Ofir G., Melamed S., Sberro H., Mukamel Z., Silverman S., Yaakov G., Doron S.,Sorek R. DISARM is a widespread bacterial defence system with broad anti-phage activities. Nat Microbiol. 2018;3:90–98.

25. Goldfarb T., Sberro H., Weinstock E., et al. BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. 2015;34(2):169–183. Doi:10.15252/embj.201489455.

26. Swarts D.C., Jore M.M., Westra E.R., Zhu Y., Janssen J.H., Snijders A.P.,Wang Y., Patel D.J., Berenguer J., Brouns S.J.J., van der Oost J. DNA-guided DNA interference by a prokaryotic Argonaute. Nature. 2014;507:258–261.

27. Bondy-Denomy J., Pawluk A., Maxwell K.L., Davidson A.R. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature. 2013;493:429–432.

28. Torres-Barcelo C. Phage therapy faces evolutionary challenges. Viruses 2018;10. pii: E323. Doi: 10.3390/v10060323.

29. Stanley S.Y., Borges A.L., Chen K.H., Swaney D.L., Krogan N.J., Bondy-Denomy J., Davidson A.R. Anti-CRISPR-associated proteins are crucial repressors of anti-CRISPR transcription. Cell. 2019;178:1452–1464.e1413.

30. Handbook of microbiological and virological diagnostic methods/ pod red. M.O. Birgera. M.:Medicina, 1982. Russian (Справочник по микробиологическим и вирусологическим методам исследования/ под ред. М.О. Биргера. М.: Медицина, 1982).

31. d’Herelle F. Sur un microbein visible antagoniste des bacteries dysenteriques. C.R. Acad. Sci. 1917;165:373–375.

32. Sulakvelidze A., Alavidze Z., Morris J.G. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649–659. Doi: 10.1128/AAC.45.3.649-659.2001.

33. Akimkin V.G., Efimenko N.A. The use of bacteriophages for the treatment of various surgical and therapeutic disorders. Metodicheskie rekomendacii. M., 1998. s. 24. Russian (Акимкин В.Г., Ефименко Н.А. Использование бактериофагов в практике лечения различных патологий хирургического и терапевтического профиля. Методические рекомендации. М., 1998. С. 24).

34. Hodyra-Stefaniak K., Miernikiewicz P., Drapała J., Drab M., JończykMatysiak E., Lecion D., Kaźmierczak Z., Beta W., Majewska J., Harhala M., Bubak B., Kłopot A., Górski A., Dąbrowska K. Mammalian HostVersus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5:14802. Doi: 10.1038/srep14802.

35. Carlton R.M. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999;47:267–274.

36. Hicks L.A., Bartoces M.G., Roberts R.M., Suda K.J., Hunkler R.J., Taylor T.H.,Schrag S.J. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis 2015;60:1308–1316. Doi: 10.1093/cid/civ076],

37. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N.,Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M.,Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057–1098. Doi: 10.1016/S1473-3099(13)70318-9.

38. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B.,Scheld M., Spellberg B., Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12. Doi: 10.1086/595011.

39. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165–170.

40. Luepke K.H., Suda K.J., Boucher H., Russo R.L., Bonney M.W., Hunt T.D., Mohr J.F. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications. Pharmacotherapy. 2017;37:71–84. Doi: 10.1002/phar.1868.

41. Parfenjuk R.L. Microbiological basics of oral phage therapy for purulent and inflammatory diseases. Avtoref. diss. kand. biol. nauk. M., 2004. 24 s. Russian (Парфенюк Р.Л. Микробиологические основы пероральной фаготерапии гнойно-воспалительных заболеваний. Автореф. дисс. канд. биол. наук. М., 2004. 24 с.).

42. Trushkov A.G. Problems of perinatology and reproductive health: Sbornik nauchnyh trudov, posvjashhennyh 25-letiju kafedry AiG GOU VPO «PGMA MZ RF». Perm', 2002. S. 213–215. Russian (Трушков А.Г. Проблемы перинатологии и репродуктивного здоровья: Сборник научных трудов, посвященных 25-летию кафедры АиГ ГОУ ВПО «ПГМА МЗ РФ». Пермь, 2002. С. 213–215).

43. Subbotin A.V., Funker E.V., Urman M.G., Gorovic Je.S., Maslov Ju.N., Odincova O.V. «Health and Education: Materials of the International Scientific and Practical Conference», Perm', 2006, s.191-197. Russian (Субботин А.В., Функер Е.В., Урман М.Г., Горовиц Э.С., Маслов Ю.Н., Одинцова О.В. Здоровье и образование: Материалы международной научно-практической конференции, Пермь, 2006. С. 191–197).

44. Tokarev M.V., Davidov M.I., Funkner E.V. Actual issues of clinical medicine: sbornik nauchnyh trudov, posvjashhennyj 130-letiju Permskoj GKB #6. Perm', 2005. S. 45–47. Russian (Токарев М.В., Давидов М.И., Функнер Е.В. Актуальные вопросы клинической медицины: сборник научных трудов, посвященный 130-летию Пермской ГКБ №6. Пермь, 2005. С. 45–47).

45. Lazareva E.B. Bacteriophages and pectins for the correction of microbiocenosis disorders in patients with purulent and inflammatory processes. Avtoref. dis. … dokt. med. nauk. M., 2007. s. 51. Russian (Лазарева Е.Б. Бактериофаги и пектины в коррекции нарушений микробиоценозов при гнойно-воспалительных процессах. Автореф. дисс. докт. мед. наук. М., 2007. С. 51).

46. Gostishhev V.K., Stanoevich U.S., Aleshkin V.A., Afanas'ev S.S et al. Tertiary peritonitis: the possibilities for the prevention. Hirurgija. 2007;9:15–18. Rusian (Гостищев В.К., Станоевич У.С., Алешкин В.А., Афанасьев С.С и др. Третичный перитонит: возможности его профилактики. Хирургия. 2007;9:15–18).

47. Hajrullin I.N., Pozdeev O.K., Shajmardanov R.Sh. The efficiency of the use of specific bacteriophages for the treatment and prevention of postoperative infections. Kazanskij medicinskij zhurnal. 2002;83(4). Russian (Хайруллин И.Н., Поздеев О.К., Шаймарданов Р.Ш. Эффективность применения специфических бактериофагов в лечении и профилактике хирургических послеоперационных инфекций. Казанский медицинский журнал. 2002;83(4)).

48. Kutateladze M., Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38:426–430.

49. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591–595.

50. Slopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz). 1987;35:569–583.

51. Lang G., Kehr P., Mathevon H., Clavert J.M., Sejourne P., Pointu J. Bacteriophage therapy of septic complications of orthopaedic surgery (author’s transl. Rev Chir Orthop Reparatrice Appar Mot. 1979;65:33–37.

52. Prokopenko E.I., Shherbakova E.O., Vatazin A.V., Budnikova N.E. et al. The use of a bacteriophage for the treatment of septic complications in patients with renal allografts. Urologiia. 2005;6:43–46. Rusian (Прокопенко Е.И., Щербакова Е.О., Ватазин А.В., Будникова Н.Е. и др. Применение бактериофага для лечения гнойно-септических осложнений у больной с почечным аллотрансплантатом. Урология. 2005;6:43–46).

53. Perepanova T.S., Darbeeva O.S., Kotljarova G.A., Kondrat'eva E.M., Majskaja L.M., Malysheva V.F., Bajguzina F.A., Grishkova N.V. The efficiency of bacteriophages for the treatment of urological inflammatory diseases. Urologiia i nefrologiia. 1995;5:14–17. Rusian (Перепанова Т.С., Дарбеева О.С., Котлярова Г.А., Кондратьева Е.М., Майская Л.М., Малышева В.Ф., Байгузина Ф.А., Гришкова Н.В.Эффективность препаратов бактериофагов при лечении воспалительных урологических заболеваний. Урология и нефрология. 1995;5:14–17).

54. Zorkin S.N., Shahnovskij D.S. Possibilities of bacteriophage therapy in the treatment of patients with complicated urinary tract infections. Pediatricheskaja farmakologija. 2013;10(4):132–138. https://doi.org/10.15690/pf.v10i4.767. Russian (Зоркин С.Н., Шахновский Д.С. Возможности бактериофаготерапии при лечении больных с осложненной инфекцией мочевых путей. Педиатрическая фармакология. 2013;10(4):132–138. https://doi.org/10.15690/pf.v10i4.767).

55. Anikina T.A., Rjazanova S.H., Sergeeva E.N. Freshly isolated strains are the most important component for the production of adapted therapeutic and prophylactic bacteriophages. Vakcinologija, N. Novgorod, 2006. s. 3. Russian (Аникина Т.А., Рязанова С.Х., Сергеева Е.Н. Свежевыделенные штаммы возбудителей – важнейший компонент производства адаптированных лечебно-профилактических бактериофагов. Вакцинология, Н. Новгород, 2006. С. 3).

56. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322.

57. Tolordava Ye.R. The role of bacterial biofilms in the etiopathogenesis of urinary stone disease. Avtoreferat diss. kand. biol. nauk. M., 2014. 26 s. Russian (Толордава Э.Р. Роль бактериальных биопленок в этиопатогенезе мочекаменной болезни. Автореферат дисс. канд. биол. наук. М., 2014. 26 с.).

58. Ferry T., Leboucher G., Fevre C., Herry Y., Conrad A., Josse J., Batailler C.,Chidiac C., Medina M., Lustig S., Laurent F. Salvage debridement, antibiotics and implant retention (“DAIR”) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureus prosthetic-joint infection? Open Forum Infect Dis 2018;5: ofy269. Doi: 10.1093/ofid/ofy269.

59. Nir-Paz R., Gelman D., Khouri A., Sisson B.M., Fackler J., Alkalay-Oren S., Khalifa L., Rimon A., Yerushalmy O., Bader R., Amit S., CoppenhagenGlazer S.,Henry M., Quinones J., Malagon F., Biswas B., Moses A.E., Merril G., Schooley R.T., Brownstein M.J., Weil Y.A., Hazan R. Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019;69:2015–2018.

60. Onsea J., Soentjens P., Djebara S., Merabishvili M., Depypere M., Spriet I.,De Munter P., Debaveye Y., Nijs S., Vanderschot P., Wagemans J., Pirnay J.P.,Lavigne R., Metsemakers W.J. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses 2019;11. pii: E891. Doi: 10.3390/v11100891;

61. Tkhilaishvili T., Winkler T., Muller M., Perka C., Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019;64. pii: e00924-19. Doi: 10.1128/AAC.00924-19.

62. Wright A., Hawkins C.H., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 2009;34:349–357. Doi: 10.1111/j.1749-4486.2009.01973.x.

63. Fadlallah A., Chelala E., Legeais J.M. Corneal infection therapy with topical bacteriophage administration. 2015;9:167–168. Doi:10.2174/1874364101509010167.

64. Totté J.E.E., van Doorn M.B., Pasmans S.G.M.A. Successful treatment of chronic Staphylococcus aureus-related dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases. Case Rep. Dermatol. 2017;9:19–25. Doi:10.1159/ 000473872.

65. Jennes S., Merabishvili M., Soentjens P., Pang K.W., Rose T., Keersebilck E.et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury – a case report. Crit. Care. 2017;21:129. Doi:10.1186/s13054-017-1709-y.

66. Jault P., Leclerc T., Jennes S., Pirnay J.P., Que Y.A., Resch G., Rousseau A.F.,Ravat F., Carsin H., Le Floch R., Schaal J.V., Soler C., Fevre C., Arnaud I.,Bretaudeau L., Gabard J. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2018;19:35–45.

67. Rohde C., Wittmann J., Kutter E. Bacteriophages: a therapy concept against multi- drug-resistant bacteria. Surg Infect (Larchmt). 2018;19:737–744.

68. Perepanova T.S., Merinov D.S., Kazachenko A.V., Hazan P.L., Malova Ju.A. Prevention of infectious and inflammatory complications after percutaneous nephrolithotripsy. Urologiia. 2020;3:26–34. Russian (Перепанова Т.С., Меринов Д.С., Казаченко А.В., Хазан П.Л., Малова Ю.А. Профилактика инфекционно-воспалительных осложнений после перкутанной нефролитотрипсии. Урология. 2020;3:26–34).

69. Malik D.J., Sokolov I.J., Vinner G.K., Mancuso F., Cinquerrui S., Vladisavljevic G.T., Clokie M.R.J., Garton N.J., Stapley A.G.F., Kirpichnikova A. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017;249:100–133.

70. Wagemans O.J., Pirnay J.P., Di Luca M., Gonzalez-Moreno M., Lavigne R., Trampuz A.,Moriarty T.F., Metsemakers W-J. Bacteriophage therapy as a treatment strategy for orthopaedic-device-related infections:where do we stand? European Cells and Materials. 2020;39:193–210. Doi: 10 .22203/eCM.v039 a13 J.

71. Merabishvili M., Monserez R., van Belleghem J., Rose T., Jennes S., De Vos D.,Verbeken G., Vaneechoutte M., Pirnay J.P. Stability of bacteriophages in burn wound care products. PLoS One 2017;12:e0182121. Doi: 10.1371/journal.pone.0182121.

72. Cisek A.A., Dabrowska I., Gregorczyk K.P., Wyzewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74:277–283.

73. Hodyra-Stefaniak K., Miernikiewicz P., Drapala J., Drab M., Jonczyk-Matysiak E., Lecion D., Kazmierczak Z., Beta W., Majewska J., Harhala M., Bubak B., Klopot A., Gorski A., Dabrowska K. Mammalian hostversus-phage immune response determines phage fate in vivo. Sci Repю 2015;5:14802. Doi: 10.1038/srep14802.

74. Roach D.R., Leung C.Y., Henry M., Morello E., Singh D., Di Santo J.P., Weitz J.S., Debarbieux L. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22:38–47.

75. Aleshkin A.V., Sel'kova E.P., Ershova O.N., Savin I.A., Shkoda A.S., Bochkareva S.S., Mitrohin S.D., Kiseleva I.A., Orlova O.E., Rubal'skiy E.O., Zul'karneev Ye.R. The concept of personalized phage therapy for patients in the intensive care unit with nosocomial infections. Fundamental'naja i klinicheskaja medicina. 2018;3(2):66–73. doi 10.23946/2500-0764-2018-3-2-66-74. Russian (Алешкин А.В., Селькова Е.П., Ершова О.Н.,Савин И.А., Шкода А.С., Бочкарева С.С., Митрохин С.Д., Киселева И.А., Орлова О.Е., Рубальский Е.О., Зулькарнеев Э.Р. Концепция персонализированной фаготерапии пациентов отделения реанимации и интенсивной терапии, страдающих инфекциями, связанными с оказанием медицинской помощи. Фундаментальная и клиническая медицина. 2018;3(2):66–73. doi 10.23946/2500-0764-2018-3-2-66-74).

76. Abedon S.T., Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11:28–47.

77. Dufour N., Delattre R., Ricard J.D., Debarbieux L. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by betalactams. Clin Infect Dis. 2017;64:1582–1588.

78. Van Belleghem J.D., Merabishvili M., Vergauwen B., Lavigne R., Vaneechoutte M.A comparative study of different strategies for removal of endotoxins from bacteriophage preparations. J Microbiol Methods. 2017;132:153–159.

79. Kutter E., De Vos D., Gvasalia G., Alavidze Z., Gogokhia L., Kuhl S., Abedon S.T.Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11:69–86.

80. Pires D.P., Oliveira H., Melo L.D., Sillankorva S., Azeredo J. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol. 2016;100:21412151.

81. Payne R.J., Jansen V.A. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42:315–325.

82. Chan B.K., Abedon S.T., Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8:769–783.

83. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage. 2011;1:111–114.

84. Haddad Kashani H., Schmelcher M., Sabzalipoor H., Seyed Hosseini E.,Moniri R. Recombinant endolysins as potential therapeutics against antibioticresistant Staphylococcus aureus: current status of research and novel delivery strategies. Clin Microbiol Rev. 2018; 31. pii: e00071-17. Doi: 10.1128/CMR.00071-17.

85. Briers Y., Lavigne R. Breaking barriers: expansion of the use of endolysins as novel antibacterials against Gram-negative bacteria. Future Microbiol. 2015;10:377–390.

86. Defraine V., Schuermans J., Grymonprez B., Govers S.K., Aertsen A., Fauvart M.,Michiels J., Lavigne R., Briers Y. Efficacy of artilysin Art-175 against resistant and persistent Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3480–3488.

87. Schirmeier E., Zimmermann P., Hofmann V., Biebl M., Gerstmans H., Maervoet V.E.T., Briers Y. Inhibitory and bactericidal effect of Artilysin® Art-175 against colistin-resistant mcr-1-positive Escherichia coli isolates. Int J Antimicrob Agents. 2018;51:528–529.

86. Wroe J.A., Johnson C.T., Garcia A.J. Bacteriophage delivering hydrogels reduce biofilm formation in vitro and infection in vivo. J Biomed Mater Res A. 2019;108:39–49.

87. Cobb L.H., Park J., Swanson E.A., Beard M.C., McCabe E.M., Rourke A.S., Seo K.S., Olivier A.K., Priddy L.B. CRISPR-Cas9 modified bacteriophage for treatment of Staphylococcus aureus induced osteomyelitis and soft tissue infection. PLoS One. 2019;14:e0220421. Doi: 10.1371/journal.pone.0220421.